Ada–Pfizer Innovation Hub & Rare Disease Collaboration
More than 300 million people are living with a rare disease, and it takes an average of 5–7 years for these people to receive an accurate diagnosis and effective treatment. The timeliness of diagnosis and treatment has a profound impact on rare disease patients' ability to live a happy, healthy life.
Ada's Medical Content department is collaborating with Pfizer’s Healthcare Hub and Rare Disease division to help patients and doctors by reducing the time required to detect amyloidosis and acromegaly. These two highly under-diagnosed conditions affect multiple organ systems and can be life-threatening if left untreated.
This collaboration combines Ada's AI-powered disease detection capabilities and Pfizer's treatment options to improve health outcomes for people with amyloidosis and acromegaly.